{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T18:38:30Z","timestamp":1771353510178,"version":"3.50.1"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1097\/md.0000000000009443","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T15:54:31Z","timestamp":1514390071000},"page":"e9443","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of micafungin for the treatment of patients with proven or probable invasive aspergillosis"],"prefix":"10.1097","volume":"96","author":[{"given":"Yu","family":"Ji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xielan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-35-20210226","first-page":"862","article-title":"Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program","volume":"86","author":"Pagano","year":"2001","journal-title":"Haematologica"},{"key":"R2-35-20210226","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1128\/CMR.18.1.44-69.2005","article-title":"Aspergillus infections in transplant recipients","volume":"18","author":"Singh","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"R3-35-20210226","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R4-35-20210226","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2003-02-0456","article-title":"Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning","volume":"102","author":"Fukuda","year":"2003","journal-title":"Blood"},{"key":"R5-35-20210226","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1086\/517849","article-title":"Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality\u2013SEIFEM-C Report","volume":"44","author":"Pagano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R6-35-20210226","first-page":"85","article-title":"Invasive fungal infections in transplant recipients","volume":"1","author":"Vazquez","year":"2013","journal-title":"Ther Adv Infect Dis"},{"key":"R7-35-20210226","first-page":"175","article-title":"Epidemiology and treatment approaches in management of invasive fungal infections","volume":"3","author":"Kriengkauykiat","year":"2011","journal-title":"Clin Epidemiol"},{"key":"R8-35-20210226","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1086\/323900","article-title":"The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis","volume":"33","author":"Perfect","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R9-35-20210226","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R10-35-20210226","first-page":"116","article-title":"Sinonasal aspergillosis with intracranial extension in an immunocompetent patient: a rare disease with typical imaging features","volume":"20","author":"Pons","year":"2014","journal-title":"Rev Chil Radiol"},{"key":"R11-35-20210226","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R12-35-20210226","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13054-014-0722-7","article-title":"Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes","volume":"19","author":"Taccone","year":"2015","journal-title":"Crit Care"},{"key":"R13-35-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12642","article-title":"Up to date epidemiology, diagnosis and management of invasive fungal infections","volume":"20","author":"Oren","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R14-35-20210226","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/JCM.01155-09","article-title":"In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method","volume":"47","author":"Pfaller","year":"2009","journal-title":"J Clin Microbiol"},{"key":"R15-35-20210226","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R16-35-20210226","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00277-015-2545-2","article-title":"Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study","volume":"95","author":"Jeong","year":"2016","journal-title":"Ann Hematol"},{"key":"R17-35-20210226","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.bbmt.2012.03.014","article-title":"Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant","volume":"18","author":"Huang","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R18-35-20210226","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jinf.2014.01.007","article-title":"Micafungin for the treatment of invasive aspergillosis","volume":"68","author":"Enoch","year":"2014","journal-title":"J Infect"},{"key":"R19-35-20210226","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jinf.2006.03.003","article-title":"Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis","volume":"53","author":"Denning","year":"2006","journal-title":"J Infect"},{"key":"R20-35-20210226","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/myc.12274","article-title":"Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis","volume":"58","author":"Cornely","year":"2015","journal-title":"Mycoses"},{"key":"R21-35-20210226","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10096-012-1754-z","article-title":"A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis","volume":"32","author":"Kohno","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R24-35-20210226","first-page":"3851","article-title":"Characteristics of invasive fungal infections secondary to COPD and its treatment with antifungal drugs","volume":"16","author":"Yang","year":"2013","journal-title":"Chin Gen Pract"},{"key":"R25-35-20210226","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R26-35-20210226","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"R27-35-20210226","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s10156-011-0219-0","article-title":"Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report","volume":"17","author":"Hanadate","year":"2011","journal-title":"J Infect Chemother"},{"key":"R28-35-20210226","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s10096-012-1690-y","article-title":"Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial","volume":"31","author":"Cadranel","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R29-35-20210226","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bmt.2009.334","article-title":"Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study","volume":"45","author":"Herbrecht","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"R30-35-20210226","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/cid\/ciu911","article-title":"Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group","volume":"60","author":"Herbrecht","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R31-35-20210226","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"R32-35-20210226","first-page":"274","article-title":"Efficacy and safety of caspofungin in critically ill patients. ProCAS Study","volume":"25","author":"Leon-Gil","year":"2012","journal-title":"Rev Esp Quimioter"},{"key":"R33-35-20210226","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1471-2334-10-182","article-title":"Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry","volume":"10","author":"Maertens","year":"2010","journal-title":"BMC Infect Dis"},{"key":"R34-35-20210226","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"Viscoli","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R35-35-20210226","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1086\/429329","article-title":"Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry","volume":"40","author":"Pappas","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R36-35-20210226","doi-asserted-by":"crossref","first-page":"S392","DOI":"10.1086\/429333","article-title":"Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients","volume":"40","author":"Chandrasekar","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R37-35-20210226","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R38-35-20210226","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur Respir J"},{"key":"R39-35-20210226","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/jac\/dkp298","article-title":"Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections","volume":"64","author":"Ikawa","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R40-35-20210226","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1128\/AAC.01647-09","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients","volume":"54","author":"Walsh","year":"2010","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000009443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:49:30Z","timestamp":1620960570000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201712290-00035"}},"subtitle":["A non-comparative, multicenter, phase IV, open-label study"],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":38,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000009443","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}